Central Sleep Apnea Research Articles

The effect of central sleep apnea on sleep architecture in children with obstructive sleep apnea

ObjectiveThis study aimed to investigate how central sleep apnea (CSA) impacts sleep patterns in children with obstructive sleep apnea (OSA). MethodsChildren undergoing polysomnography (PSG) were enrolled and sorted into two groups: those with OSA alone (Group A) and those with both OSA and CSA (CAI <1 nd: children with 10 % CSA or more and less than 50 %, Group B). Statistical analysis was conducted to compare sleep structure and clinical features between Group A and Group B. ResultsGroup B exhibited significantly higher respiratory events, apnea hypoventilation index, apnea index and oxygen desaturation index (ODI) compared to Group A (p < 0.05). Group B also showed higher total sleep time and arousal index than Group A (P < 0.05). The proportion of time spent in stage N3 was lower in Group B than in Group A (P < 0.05). Moreover, mean heart rate and minimum heart rate were higher in Group B compared to Group A (P < 0.05).Minimum oxygenation levels (including non-rapid eye movement (NREM) stages) were lowe in Group B than in Group A (P < 0.05). Additionally, the prevalence of positional obstructive sleep apnea (P-OSA) was greater in Group B than in Group A (P < 0.05). ConclusionIn comparison to those with OSA alone, children with OSA and concurrent CSA exhibited distinct sleep patterns, including reduced N3uration, higher arousal index, longer respiratory events, higher ODI, and lower oxygen saturation, higher heart rate.

Cardiovascular risk factors for the diagnosis of insomnia in end-stage renal disease

BackgroundInsomnia, a known cardiovascular risk factor, is common in end-stage renal disease (ESRD) patients. There is growing acknowledgment of a potential bidirectional relationship between cardiovascular diseases and sleep disorders. We previously assessed the risk factors for common sleep disorders in ESRD patients. This follow-up study assesses the demographic and clinical cardiovascular-related risk factors for insomnia diagnosis in ESRD patients, given their increased cardiovascular burden. MethodsThis study is a retrospective analysis of the United States Renal Data System to evaluate risk factors for insomnia diagnosis. All patients in the USRDS who started dialysis between 2005 and 2019 were eligible for inclusion. Demographic risk factors analyzed were age, race, sex, ethnicity, dialysis modality, and access type. Cardiovascular risk factors, including obstructive sleep apnea (OSA) and central sleep apnea (CSA), were also evaluated. ResultsFemale sex, OSA, CSA, myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, diabetes, chronic obstructive pulmonary disease, obesity, and hypertension were associated with an increased risk of insomnia. Increasing age, non-white race, Hispanic ethnicity, and catheter or other/peritoneal dialysis access type were associated with a decreased risk of an insomnia diagnosis. ConclusionVarious cardiovascular diseases were independent risk factors for an insomnia diagnosis in this retrospective cohort. Further study is indicated to investigate potential mechanisms underlying this connection.

Phrenic nerve stimulation for central sleep apnea: a single institution experience

PurposePhrenic nerve stimulation (PNS) was approved by the Food and Drug Administration (FDA) to treat moderate to severe central sleep apnea. We report here, results of a retrospective study regarding our institutional outcomes at one year. In this study we evaluated the change in the apnea hypopnea index, epworth sleepiness score, and functional outcomes of sleep score at one year post implant.MethodsThis is a retrospective analysis of patients ≥ 18 years of age who had PNS implanted for moderate to severe CSA at the Ohio State University Wexner Medical Center apnea between Feb 1, 2018 to July 1, 2021. Sleep disordered breathing parameters and objective sleepiness as measured by the Epworth Sleepiness Scale (ESS) scores, and Functional Outcomes of Sleep Questionnaire (FOSQ) scores were assessed at baseline and one-year post-implant.ResultsTwenty-two patients were implanted with PNS at OSU between February 1, 2018 and May, 31, 2022. The AHI showed a statistically significant decrease from a median of 40 events/hour at baseline to 18 at follow-up (p-value = 0.003). The CAI decreased from 16 events/hour to 2 events/hour (p-value of 0.001). The obstructive apnea index, mixed apnea index, and hypopnea index did not significantly change. The ESS scores had a statistically significant improvement from a median score of 12 to 9 (p-value = 0.028). While the FOSQ showed a trend to improvement from 15.0 to 17.8, it was not statistically significant (p-value of 0.086).ConclusionOur study found that PNS therapy for moderate to severe CSA improves overall AHI and CAI. Objective sleepiness as measured by the ESS also improved at one-year post implant.

Characterisation of sleep apneas and respiratory circuitry in mice lacking CDKL5.

CDKL5 deficiency disorder is a rare genetic disease caused by mutations in the CDKL5 gene. Central apneas during wakefulness have been reported in patients with CDKL5 deficiency disorder. Studies on CDKL5-knockout mice, a CDKL5 deficiency disorder model, reported sleep apneas, but it is still unclear whether these events are central (central sleep apnea) or obstructive (obstructive sleep apnea) and may be related to alterations of brain circuits that modulate breathing rhythm. This study aimed to discriminate central sleep apnea and obstructive sleep apnea in CDKL5-knockout mice, and explore changes in the somatostatin neurons expressing high levels of neurokinin-1 receptors within the preBötzinger complex. Ten adult male wild-type and 12 CDKL5-knockout mice underwent electrode implantation for sleep stage discrimination and diaphragmatic activity recording, and were studied using whole-body plethysmography for 7 hr during the light (resting) period. Sleep apneas were categorised as central sleep apnea or obstructive sleep apnea based on the recorded signals. The number of somatostatin neurons in the preBötzinger complex and their neurokinin-1 receptors expression were assessed through immunohistochemistry in a sub-group of animals. CDKL5-knockout mice exhibited a higher apnea occurrence rate and a greater prevalence of obstructive sleep apnea during rapid eye movement sleep, compared with wild-type, whereas no significant difference was observed for central sleep apnea. Moreover, CDKL5-knockout mice showed a reduced number of somatostatin neurons in the preBötzinger complex, and these neurons expressed a lower level of neurokinin-1 receptors compared with wild-type controls. These findings underscore the pivotal role of CDKL5 in regulating normal breathing, suggesting its potential involvement in shaping preBötzinger complex neural circuitry and controlling respiratory muscles during sleep.

Central Sleep Apnea: An Update of Current Treatment and the Role of Positive Pressure Devices

Central Sleep Apnea: An Update of Current Treatment and the Role of Positive Pressure Devices

Development of a New Prototype Paediatric Central Sleep Apnoea Monitor

A new prototype device to monitor breathing in children diagnosed with central sleep apnoea (CSA) was developed. CSA is caused by the failure of central nervous system signals to the respiratory muscles and results in intermittent breathing pauses during sleep. Children diagnosed with CSA require home respiration monitoring during sleep. Apnoea monitors initiate an audio alarm when the breath-to-breath respiration interval exceeds a preset time. This allows the child’s parents to attend to the child to ensure safety. The article describes the development of the monitor’s hardware, software, and evaluation. Features of the device include the detection of abnormal respiratory pauses and the generation of an associated alarm, the ability to record the respiratory signal and its storage using an on-board disk, miniaturised hardware, child-friendliness, cost-effectiveness, and ease of use. The device was evaluated on 10 healthy adult volunteers with a mean age of 46.6 years (and a standard deviation of 14.4 years). The participants randomly intentionally paused their breathing during the recording. The device detected and provided an alarm when the respiratory pauses exceeded the preset time. The respiration rates determined from the device closely matched the values from a commercial respiration monitor. The study indicated the peak-detection method of the respiration rate measurement is more robust than the zero-crossing method.

Correlation of Vitamin C with Risk Factors of Coronary Artery Disease to Measure the Disease Prognosis to Prepare a Diagnostic Strategy

Abstract BACKGROUND: Reports depicted insufficient plasma Vitamin C levels and significant associations to both acute and chronic inflammation. Recently, use of intravenous Vitamin C has gained visibility for its effectiveness in coronavirus-19 treatment. There were no studies available currently to detect the clinical correlation between plasma Vitamin C with risk factors of coronary artery disease (CAD). The present aim of the study is to estimate the Vitamin C levels in CAD patients as well as to correlate with clinical and laboratory variables to assess the severity of CAD and also to formulate a diagnostic strategy. METHODS: A prospective comparative study was conducted in 100 diagnosed cases of CAD and estimate plasma Vitamin C levels and compared with healthy individuals. Spearman correlation analysis was performed between Vitamin C levels and risk factors of CAD. RESULTS: Maximum CAD cases were in the age group of 60–70 years. The mean age was 58.54 ± 11.60 years in the CAD patients. Among risk factors, 54% of patients had hypertension, 54% of patients had diabetes mellitus, and 27% of patients had dyslipidemia. There significant association noted between diabetes and type of CAD (P = 0.015). Among CAD cases, 70% of patients had ST-elevation myocardial infarction (STEMI), 11% of patients had a non-ST-elevation myocardial infarction (NSTEMI), 17% of patients had unstable angina (USA), and only 2% of patients had central sleep apnoea (CSA). Angiogram diagnosis shows that 34% of patients had single-vessel disease (SVD), 28% of patients had double-vessel disease (DVD), 8% of patients had triple-vessel disease (TVD), 2% of patients had left main coronary artery (LMCA) disease, 13% patients had mild CAD, and 15% patients had normal epicardial coronaries. The range of plasma Vitamin C concentrations level was from 33.25 to 92.5 μmol/L in CAD patients. The mean plasma Vitamin C concentration levels in CAD patients were lower than in healthy individuals (66.96 ± 13.6 vs. 71.33 ± 10.8 μmol/L). There was no statistically significant difference between CAD and non-CAD for plasma Vitamin C concentration levels (P = 0.085). The mean Vitamin C level was higher in DVD (70.6 ± 10.9) than the TVD, LM (71.6 ± 5.82), SVD (68.49 ± 12.4), mild CAD (65.55 ± 13.1), and TVD (62.92 ± 8.9). There was no statistically significant difference in plasma Vitamin C levels in the coronary angiogram (CAG) diagnosis for CAD cases (P = 0.103). The mean plasma Vitamin C levels were higher in NSTEMI (72.98 ± 10.8) than the STEMI (69.5 ± 12.5), USA (63.6 ± 15.2), and CSA (58.45 ± 3.5) μmol/L. There was no statistically significant difference in plasma Vitamin C levels in the type of CAD (P = 0.135). A negative correlation is noted between Vitamin C and low-density lipoprotein (LDL) cholesterol (r = −0.32, P = 0.02). Similarly, there is a negative correlation between Vitamin C and TGL (r = −0.28, P = 0.0067), whereas there is a positive correlation between Vitamin C and high-density lipoprotein (HDL) (r = 0.27, P = 0.0025). CONCLUSION: The mean of Vitamin C concentration levels was lower in CAD patients than in healthy individuals. There is a significant negative correlation between Vitamin C and LDL and between Vitamin-C and TGL. A positive correlation was observed between Vitamin-C and HDL. Vitamin C along with HDL was markedly decreased in CAD and may be the cause. Hence, the combination of Vitamin C, LDL, and HDL can be considered prognostic detectors to know the CAD at its early stages.

Pulmonary hypertension in patients affected by sleep-related breathing disorders: up to date from the literature.

Sleep-related breathing disorders (SBD) are conditions of abnormal and difficult respiration during sleep, including chronic snoring, obstructive sleep apnea (OSA), central sleep apnea (CSA), sleep-related hypoventilation disorders and sleep-related hypoxemia. Some of them have a limited impact on health, but others (e.g., OSA) can have serious consequences, because of their dangerous effects on sleep and the hematic balance of oxygen and carbon dioxide. According to several population-based studies, prevalence of OSA is relatively high, approximately 3-7% for adult males and 2-5% for adult females in the general population. However, methodological differences and difficulties in characterizing this syndrome yielded to variability in estimates. Moreover, it is estimated that only about 40% of patients with OSA are diagnosed, which can lead to underestimation of disease prevalence. OSA is directly correlated with age and male sex and to risk factors such as obesity. Several studies found that OSA is associated with an increased risk of diabetes, some cancer types, cardiovascular and cerebrovascular diseases, such as hypertension, coronary artery disease and stroke. Pulmonary hypertension (PH), a noted cardiovascular disease, is significantly associated with sleep-related breathing disorders and lot of scientific studies published in the literature demonstrated a strong link between these conditions and the development of pulmonary hypertension PH. PH is relatively less common than sleep-related breathing disorders. The purpose of this systematic review is to analyze both the current knowledge around the consequences that SBD may have on pulmonary hemodynamics and the effects resulting from pharmacological and non-pharmacological treatments of SDB on PH.

Sleep-disordered breathing in children with Chiari type I malformation.

The objective was to identify clinical and radiological factors associated with sleep-disordered breathing (SDB) in children with Chiari type I malformation (CIM) and to evaluate the efficacy of foramen magnum decompression (FMD) in resolving SDB. A retrospective chart review was conducted for all children evaluated for CIM at a single institution from 2002 to 2022, identifying all children who had undergone nocturnal polysomnography (PSG). Apnea-hypopnea index (AHI) score, sleep apnea type (obstructive, central, mixed, and unspecified), clinical manifestations, and radiological measurements were recorded. SDB was considered present when officially diagnosed in the PSG report. Logistic regression was performed to identify factors correlating with the presence of SDB. For children with SDB who underwent FMD, the Wilcoxon signed-rank test was used to assess AHI improvement. Of the 997 children referred for CIM, 310 completed PSG. SDB was diagnosed in 147 patients (overall prevalence 14.7%, 95% CI 12.7%-17.1%; prevalence among children with PSG 47.4%, 95% CI 41.9%-53%). Specific SDB diagnosis consisted of 33% of patients with central sleep apnea, 27% with obstructive sleep apnea, 9% mixed, and 31% unspecified. Lower cranial nerve (CN) dysfunction (OR 3.891, p = 0.009), tonsillar position (OR 1.049, p = 0.017), Chiari type 1.5 malformation (OR 1.862, p = 0.044), and BMI (OR 1.039, p = 0.036) were significantly associated with presence of SDB. Of the 310 patients who underwent PSG, 47 were originally categorized as asymptomatic: 27 (57%) of these asymptomatic patients were diagnosed with SDB on PSG. Of children diagnosed with SDB, 34 completed PSG before and after FMD. Median AHI score decreased from 6.5 preoperatively to 1.8 postoperatively, with a median (IQR) difference of -2.3 (-11.9 to 0.1) (p = 0.001). Twelve (35%) had resolution of SDB. The authors' findings suggest that the prevalence of SDB in children with CIM is high (15%-47%). Furthermore, lower CN dysfunction, Chiari type 1.5, lower tonsillar position, and higher BMI may be risk factors. Notably, SDB can be present even in the absence of clinical symptoms. This study also demonstrates that surgical intervention has the potential to reduce the severity of SDB. These results could help clinicians identify CIM patients at risk for SDB and those who may benefit from surgical decompression.

Epidemiological Study of Sleep Apnea Prevalence and Associated Risk Factors in a Large Patient Population.

Significant morbidity and death are linked to sleep apnea (SP), a prevalent sleep disease. For successful management, it is essential to comprehend its prevalence and the risk factors that are linked with it. The purpose of this study was to look at the prevalence of SP in a large patient group that was visiting a tertiary care facility and to discover risk variables that are connected with it. 500 volunteers were gathered from a tertiary care center to participate in cross-sectional research. Polysomnography, clinical evaluations, and standardized questionnaires were utilized to diagnose SP and gather pertinent information. A statistical study was conducted to evaluate the correlation between different risk factors and SP. 35% of people had SP, with men between the ages of 40 and 60 having a greater frequency. It has been determined that smoking, obesity, and high blood pressure are important risk factors for SP. Compared to those with mild or moderate SP, individuals with severe SP had greater rates of smoking, hypertension, and obesity (BMI > 30). This study emphasizes how common SP is in tertiary care settings and how it is linked to smoking, obesity, and hypertension. Improving patient outcomes and lessening the impact of SP need early identification and management techniques that address these modifiable risk factors.

The Morbid Impact of Environmental Toxins on the Human Nervous System: Central Sleep Apnea Nexus with Organic Solvents, Pesticides, and Heavy Metals

The Morbid Impact of Environmental Toxins on the Human Nervous System: Central Sleep Apnea Nexus with Organic Solvents, Pesticides, and Heavy Metals

Sleep disorders in pediatric patients with agenesis of the corpus callosum.

There is limited information about sleep in agenesis of the corpus callosum (ACC). We aim to describe the sleep architecture and respiratory parameters of children with ACC. We performed a retrospective study of 20 patients with ACC who had polysomnography between 2000 and 2023. Demographic data, body mass index or weight for length, associated conditions, and polysomnography findings were collected. National Sleep Foundation sleep quality indicators as well as increased polysomnography arousal index ≥ 10 events/h were used in the analysis. Fisher's exact test or unpaired t test was used to compare groups. Average age was 5.9 ± 5.4 years old. A total of 12/20 patients were male; 6/20 were overweight/obese; 14/20 had complete ACC, and 6/20 had partial ACC; 8/20 had seizures; 15/20 had ≥ 1 National Sleep Foundation poor sleep quality indicator (decreased sleep efficiency [45%], decreased rapid eye movement sleep [53%]); and 9/20 had increased arousals. Between complete and partial ACC, there was no difference in presence of ≥ 1 poor sleep quality indicator (P = .61), sleep efficiency (P = .34), rapid eye movement sleep (P = .28), and arousals (P = 1.0). 11/18 had obstructive sleep apnea (OSA); 5/11 had associated central sleep apnea. There was no difference in OSA between those with complete and partial ACC (P = 1.0). OSA was associated with children < 3 years old (P = .01). Children with ACC have poor sleep quality, and many have OSA. There was no difference in sleep quality or presence of OSA between those with complete and partial ACC. OSA was seen more in younger children. Our study supports the need for screening of sleep-related disorders in patients with ACC. Kwon A, Gu PK, Zhang C, Davidson Ward SL, Perez IA. Sleep disorders in pediatric patients with agenesis of the corpus callosum. J Clin Sleep Med. 2024;20(10):1663-1667.

Screening Strategies for Sleep-Disordered Breathing in Patients With Spinal Cord Injury in a Tertiary Care Rehabilitation Center.

Sleep-disordered breathing (SDB) is frequent in patients with spinal-cord injury (SCI). However, SDB is frequently underdiagnosed due to limited access to diagnostic testing and knowledge about the condition. Moreover, SDB heterogeneity (sleep apnea, obstructive sleep apnea or central sleep apnea and nocturnal alveolar hypoventilation) implies complex evaluation of both nocturnal respiratory effort and hypercapnia. The aim of this study was to compare different screening strategies for an SDB diagnosis in patients with SCI. This was a retrospective analysis of data from subjects with SCI followed up in a tertiary-care rehabilitation center with a specialized sleep unit. Subjective (questionnaires) and objective data (polysomnography [PSG]), [Formula: see text] extracted from the PSG, morning blood gases, and nocturnal transcutaneous CO2 (PtcCO2 ) were collected and analyzed. A retrospective comparison of different strategies for SDB screening was carried out. Each strategy was compared (alone and in combination) with the standard of care for sleep apnea (PSG) and nocturnal alveolar hypoventilation (PtcCO2 ) diagnosis. The performance of the usual cutoff and visual analysis was studied. Among 190 subjects with SCI who underwent a full night's PSG, data were available for 104 questionnaires and 162 with oximetry. Nocturnal alveolar hypoventilation was screened by PtcCO2 and blood gases in 52 subjects with SCI. Questionnaires (the modified Screening for Obstructive Sleep Apnea in Tetraplegia and the Epworth Sleepiness Scale) had poor performance for identifying sleep apnea and did not identify nocturnal alveolar hypoventilation. [Formula: see text] (oxygen desaturation index score ≥ 13) and visual analysis of [Formula: see text] were good at identifying sleep apnea but insufficient to identify nocturnal alveolar hypoventilation. Diurnal blood gases were poor predictors of nocturnal alveolar hypoventilation. Questionnaires were of limited use in subjects with SCI, but the oxygen desaturation index derived from oximetry performed well for sleep apnea screening. Both diurnal blood gases and oximetry visual analysis were insufficient for nocturnal alveolar hypoventilation screening. PtcCO2 monitoring should be mandatory and ideally combined with PSG given the heterogeneity of SDB phenotypes and associated sleep comorbidities of patients with SCI.

Treatment-Emergent Central Sleep Apnea (TECSA) with Chronic Use of Mandibular Advancement Device (MAD): A Case Series

Treatment-Emergent Central Sleep Apnea (TECSA) with Chronic Use of Mandibular Advancement Device (MAD): A Case Series

Central sleep apnea in chronic heart failure with hypoxemia - treatment efficacy and hemodynamic effects of three different treatment modalities: a case report

BackgroundThe optimal treatment for central sleep apnea (CSA) depends on the underlying pathophysiology and should consider the potential for hemodynamic impairment when using positive airway pressure devices. While the long-term effects on overall cardiovascular outcome have been investigated for different device settings, the immediate hemodynamic consequences are not well understood. This is mainly due to a lack of hemodynamic monitoring during routine polysomnographic assessment. The application of most monitoring devices is either restricted by their invasiveness, e.g. in thermodilution, or cannot be used continuously like in echocardiography. Impedance cardiography (ICG), however, enables physicians to implement a continuous non-invasive monitoring of different hemodynamic parameters which can be useful in various clinical scenarios. In sleep medicine, the hemodynamic effect of initiating positive airway pressure treatment in patients with pre-existing heart failure should be of special concern.Case presentationIn this case report, we compare the efficacy of three different treatment modalities in a patient with CSA related to chronic heart failure considering the resolution of respiratory events on polysomnography (PSG). In addition, we outline the hemodynamic effects of each treatment device using ICG for non-invasive hemodynamic monitoring. Regarding the reduction of respiratory central events, long-term oxygen treatment (LTOT) and adaptive servoventilation (ASV) proved to be more efficient compared with automatic positive airway pressure (APAP). Hemodynamically, substantial differences of the cardiac performance were observed between the treatment devices. This especially applied to ASV which led to a pronounced drop in cardiac output.ConclusionOur case report indicates that treatment of CSA may induce significant changes of hemodynamic parameters which would remain undetected during routine polysomnographic assessment. We conclude that non-invasive hemodynamic monitoring may be considered when positive airway pressure treatment is initiated in patients at risk of hemodynamic impairment.

Sleep disorders in chronic kidney disease.

Sleep disorders are highly prevalent in chronic kidney disease (CKD) but are often under-recognized. Restless legs syndrome, which is common in CKD owing to issues with dopamine metabolism and is exacerbated by iron deficiency and uraemia, can lead to poor sleep quality and increased daytime fatigue. Insomnia is also prevalent in CKD, particularly in patients requiring dialysis, with increased sleep latency and sleep fragmentation being reported. The cause of insomnia in CKD is multifactorial - poor sleep habits and frequent napping during dialysis, uraemia, medications and mood disorders have all been suggested as potential contributing factors. Sleep apnoea and CKD are also now recognized as having a bi-directional relationship. Sleep apnoea is a risk factor for accelerated progression of CKD, and fluid overload, which is associated with kidney failure, can lead to both obstructive and central sleep apnoea. The presence of obstructive sleep apnoea in CKD can exacerbate the already heightened cardiovascular morbidity and mortality in these patients, as well as leading to daytime fatigue and reduced quality of life. Increased awareness, timely diagnosis and appropriate therapeutic interventions are essential to reduce the negative impact of sleep disorders in patients with kidney disease.

Cardiovascular disease and sleep apnea in patients with type 2 diabetes mellitus

The article provides information on concomitant conditions of type 2 diabetes mellitus such as cardiovascular diseases, sleep apnea syndrome. Questions about the types of sleep breathing disorders and factors predisposing to this condition are discussed. Data on the prevalence of sleep apnea in the world are demonstrated. The main approaches to the diagnosis of this condition are shown. Differences in therapy approaches for obstructive sleep apnea and central sleep apnea have been demonstrated. The issues of the relationship between obstructive sleep apnea, type 2 diabetes mellitus and cardiovascular diseases are considered. The data of clinical studies evaluating the relationship of sleep apnea and cardiovascular diseases are presented. Their mutually aggravating influence is shown. Information is provided on the effect of sleep apnea on the main clinical outcomes according to clinical research data. The relationship between sleep apnea and heart failure is discussed. The main issues of the inflammatory profile of sleep apnea are discussed, which are closely related to cardiovascular diseases and type 2 diabetes and include: macrophage recruitment and inflammatory biomarkers such as C-reactive protein, chemokines and cytokines such as interleukin 6, tumor necrosis factor α, nuclear kappa factor B, as well as adhesion molecules such as selectins, intracellular adhesion molecule-1 (ICAM-1) and intracellular vascular adhesion molecule (VCAM-1), imbalance between prooxidant and antioxidant factors. These factors contribute to the development of microvascular and macrovascular complications in type 2 diabetes mellitus. Special attention is paid in the publication to the discussion of the main factors predisposing to the development of sleep apnea in heart failure in patients with type 2 diabetes mellitus. The data on the main diagnostic tests for patients with heart failure and type 2 diabetes are presented. Information is provided on the use of drugs from the group of sodiumglucose cotransporter type 2 inhibitors in patients with type 2 diabetes and sleep apnea syndrome. Reasonable recommendations on the use of these drugs are presented, taking into account the modern strategy for the treatment of type 2 diabetes.

Medication-induced central sleep apnea: beyond the unification of concepts, seizing the opportunity to precision medicine.

Medication-induced central sleep apnea: beyond the unification of concepts, seizing the opportunity to precision medicine.

Diagnostic and therapeutic process of respiratory disorders during sleep

Introduction and purpose Sleep apnea is a disturbance of sleep that affects about 10% of adult population and is not easily detected due to unspecific symptoms. The aim of this literature review is to present, respectively, obstructive sleep apnea and central sleep apnea symptoms and integrate the available data in the literature regarding the pathogenesis and treatment methods. Materials and methods A review of literature was performed using PubMed and Google Scholar database. The search criteria included keywords such as sleep apnea, obstructive sleep apnea treatment, central sleep apnea treatment. State of knowledge Sleep disturbances that involve breathing can be categorized as obstructive sleep apnea (OSA) and central sleep apnea. First one is associated with the obstruction of the upper airways and the second one – with malfunctioning breathing generator in the pontomedullary breathing pacemaker. Symptoms are unspecific which makes diagnostic process difficult. However, the right diagnosis and treatment may prevent patients from developing many cardiovascular diseases. Treatment options for OSA include: CPAP, reducing body weight, changing sleep position, braces and surgeries; for CSA: CPAP and acetazolamide. Conclusions OSA and CSA need to be further investigated in order to find more precise ways of diagnosis and treatment, as these diseases remain underreported. It is worth noting, that these conditions predispose to serious diseases, e.g. stroke. Therefore, developing new treatment techniques would beneficial for the health of population.

Sleep Apnea and Heart Failure-Current State-of-The-Art.

Sleep-disordered breathing (SDB), including obstructive and central sleep apnea, significantly exacerbates heart failure (HF) through adverse cardiovascular mechanisms. This review aims to synthesize existing literature to clarify the relationship between SDB and HF, focusing on the pathophysiological mechanisms, diagnostic challenges, and the effectiveness of treatment modalities like continuous positive airway pressure (CPAP) and adaptive servo-ventilation ASV. We analyzed peer-reviewed articles from 2003 to 2024 sourced from PubMed, EMBASE, Scopus, and Web of Science databases. The prevalence of SDB in HF patients is high, often underdiagnosed, and underappreciated. Management strategies, including CPAP and ASV, have been shown to mitigate symptoms and improve cardiac function. However, despite the availability of effective treatments, significant challenges in screening and diagnosis persist, affecting patient management and outcomes. DB significantly impacts HF prognosis. Enhanced screening strategies and broader utilization of therapeutic interventions like CPAP and ASV are essential to improve the management and outcomes of HF patients with concomitant SDB. Future research should focus on refining diagnostic and treatment protocols to optimize care for HF patients with SDB.